Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LKS001
MIFTS: 46

Leukostasis

Categories: Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Leukostasis

About this section

MalaCards integrated aliases for Leukostasis:

Name: Leukostasis 12 54 43 15 17 71

Classifications:

MalaCards categories:
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:12986
MeSH 43 D018921
NCIt 49 C4062
SNOMED-CT 67 30419000
UMLS 71 C0282548
Sources

Summaries for Leukostasis

About this section
MalaCards based summary : Leukostasis is related to microvascular complications of diabetes 5 and granulocytopenia. An important gene associated with Leukostasis is ICAM1 (Intercellular Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Angiotensin II and Irbesartan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, lung and endothelial, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 74 Leukostasis (also called symptomatic hyperleukocytosis) is a medical emergency most commonly seen in... more...

Sources

Related Diseases for Leukostasis

About this section

Diseases related to Leukostasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 517)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 30.9 VEGFA VCAM1 SERPINF1 KDR ICAM1 AGER
2 granulocytopenia 30.9 TNF SELL MPO
3 pulmonary edema 29.9 TNF IL1B ICAM1
4 microvascular complications of diabetes 1 29.7 VEGFA VCAM1 SERPINF1 ICAM1 CCL2 AGER
5 diabetic macular edema 29.5 VEGFA SERPINF1 IL6 ICAM1 CCL2
6 leukemia, acute myeloid 29.4 VEGFA TNF MPO KDR IL6 IL1B
7 disseminated intravascular coagulation 29.3 TNF SELE IL6
8 hyperglycemia 29.3 VCAM1 SELE IL6 AGER
9 acute pancreatitis 29.1 TNF MPO IL6 IL1B
10 congestive heart failure 29.0 VEGFA TNF IL6 IL1B
11 retinal vascular occlusion 29.0 VEGFA SERPINF1 KDR IL6 ICAM1 CCL2
12 adult respiratory distress syndrome 29.0 TNF SELE MPO IL6 IL1B
13 retinal detachment 28.8 VEGFA TNF SERPINF1 IL6 CCL2
14 monocytic leukemia 28.8 TNF MPO IL6 IL1B CCL2
15 leukemia, acute monocytic 28.6 TNF MPO IL6 IL1B CCL2
16 bacterial infectious disease 28.6 TNF SELL IL6 IL1B CCL2
17 acute promyelocytic leukemia 28.6 TNF MPO IL6 IL1B ICAM1 CCL2
18 myelodysplastic syndrome 28.5 VEGFA TNF MPO KDR IL6 IL1B
19 uveitis 28.4 TNF SERPINF1 IL6 IL1B ICAM1 CCL2
20 pneumonia 28.4 TNF SELL MPO IL6 IL1B ICAM1
21 pulmonary hypertension 28.3 VEGFA TNF KDR IL6 IL1B CCL2
22 thrombocytopenia 28.2 TNF SELL SELE IL6 IL1B ICAM1
23 macular retinal edema 27.6 VEGFA TNF SERPINF1 OCLN KDR IL6
24 eye disease 27.3 VEGFA VCAM1 TNF SERPINF1 KDR IL6
25 retinal vascular disease 27.0 VEGFA VCAM1 TNF SERPINF1 RMC1 OCLN
26 myeloid leukemia 10.7
27 leukemia 10.6
28 diabetic peripheral angiopathy 10.4 SELE ICAM1
29 leukemia, chronic myeloid 10.4
30 acute leukemia 10.4
31 heterophyiasis 10.4 SELE ICAM1
32 respiratory failure 10.4
33 mooren's ulcer 10.4 VCAM1 SELE ICAM1
34 autoimmune inner ear disease 10.3 TNF MPO
35 hydrocele 10.3 VEGFA SELE ICAM1
36 plummer's disease 10.3 SELL SELE ICAM1
37 limbal stem cell deficiency 10.3 VCAM1 IL1B ICAM1
38 microscopic polyangiitis 10.3 TNF MPO
39 neutropenia 10.3
40 chronic venous insufficiency 10.3 VEGFA VCAM1 SELL ICAM1
41 venous insufficiency 10.3 VEGFA VCAM1 SELL ICAM1
42 kuhnt-junius degeneration 10.3 VEGFA KDR CFHR2
43 severe nonproliferative diabetic retinopathy 10.3 VEGFA ICAM1 CCL2
44 gastroesophageal junction adenocarcinoma 10.3 VEGFA KDR IL1B
45 macular holes 10.3 VEGFA SERPINF1 CCL2
46 physiological polycythemia 10.2 TNF IL1B
47 immune-complex glomerulonephritis 10.2 VCAM1 MPO ICAM1 CFHR2
48 henoch-schoenlein purpura 10.2 VCAM1 MPO ICAM1 CFHR2
49 macular degeneration, age-related, 9 10.2 VCAM1 SELL SELE ICAM1
50 diabetes mellitus, insulin-dependent, 23 10.2 TNF SELL

Graphical network of the top 20 diseases related to Leukostasis:



Diseases related to Leukostasis
Sources

Symptoms & Phenotypes for Leukostasis

About this section

MGI Mouse Phenotypes related to Leukostasis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 AGER ICAM1 IL1B IL6 KDR MPO
2 hematopoietic system MP:0005397 10.36 AGER ICAM1 IL1B IL6 KDR MPO
3 cellular MP:0005384 10.35 AGER ICAM1 IL6 KDR NFATC1 NFATC2
4 growth/size/body region MP:0005378 10.35 AGER ICAM1 IL1B IL6 KDR NFATC1
5 immune system MP:0005387 10.33 AGER CCL2 ICAM1 IL1B IL6 KDR
6 homeostasis/metabolism MP:0005376 10.28 AGER ICAM1 IL1B IL6 KDR MPO
7 endocrine/exocrine gland MP:0005379 10.19 ICAM1 IL6 NFATC2 NFATC3 NFATC4 OCLN
8 digestive/alimentary MP:0005381 10.16 ICAM1 IL6 NFATC1 NFATC3 NFATC4 OCLN
9 muscle MP:0005369 10.1 AGER ICAM1 IL6 KDR MPO NFATC1
10 craniofacial MP:0005382 10.07 IL1B KDR NFATC1 NFATC2 NFATC4 TNF
11 integument MP:0010771 10.07 AGER ICAM1 IL1B IL6 KDR NFATC1
12 nervous system MP:0003631 10 ICAM1 IL1B IL6 KDR NFATC2 NFATC3
13 respiratory system MP:0005388 9.81 IL6 KDR NFATC1 NFATC2 NFATC3 SELE
14 skeleton MP:0005390 9.7 AGER IL1B IL6 KDR NFATC1 NFATC2
15 vision/eye MP:0005391 9.28 ICAM1 IL6 KDR NFATC2 NFATC3 SELE
Sources

Drugs & Therapeutics for Leukostasis

About this section

Drugs for Leukostasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 3 4474-91-3, 11128-99-7, 68521-88-0 172198
2
Irbesartan Approved, Investigational Phase 3 138402-11-6 3749
3
Olmesartan Approved, Investigational Phase 3 144689-24-7, 144689-63-4 158781 130881
4
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
5
Candesartan cilexetil Approved Phase 3 145040-37-5 2540
6
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
7
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
8
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
9
Candesartan Experimental Phase 3 139481-59-7 2541
10 Angiotensin II Type 1 Receptor Blockers Phase 3
11 Angiotensinogen Phase 3
12 Angiotensin Receptor Antagonists Phase 3
13 Antihypertensive Agents Phase 3
14 Angiotensin-Converting Enzyme Inhibitors Phase 3
15 Giapreza Phase 3
16
Olmesartan medoxomil Phase 3 144689-63-4 130881
17 2-chloro-3'-deoxyadenosine Phase 2, Phase 3
18 Immunologic Factors Phase 2, Phase 3
19 Anti-Bacterial Agents Phase 2, Phase 3
20 Immunosuppressive Agents Phase 2, Phase 3
21 Antibiotics, Antitubercular Phase 2, Phase 3
22
Curcumin Approved, Experimental, Investigational 458-37-7 969516
23
Hydroxocobalamin Approved 13422-51-0 15589840 11953898
24 Grape Approved
25
Thiamine Approved, Investigational, Nutraceutical, Vet_approved 59-43-8, 70-16-6 1130
26
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
27
Lutein Approved, Investigational, Nutraceutical 127-40-2 6433159
28
Coenzyme Q10 Approved, Investigational, Nutraceutical 303-98-0 5281915
29
Resveratrol Investigational 501-36-0 445154
30
Cobalamin Experimental 13408-78-1 6857388
31 Tea
32 Vitamins
33 Alpha-lipoic Acid
34 Carotenoids
35 Vitamin B Complex
36 Vitamin B 12
37 Thiamin
38 Antioxidants
39 Thioctic Acid
40 Maritime Pine
41 Omega 3 Fatty Acid
42 Vitamin B12
43 Ubiquinone
44 Pycnogenols

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients Unknown status NCT01992796 Phase 3 Irbesartan
2 Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
3 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
4 Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema (COLLIDE) Withdrawn NCT03629210 Phase 2 OZURDEX
5 Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema Not yet recruiting NCT03866005

Search NIH Clinical Center for Leukostasis

Cochrane evidence based reviews: leukostasis

Sources

Genetic Tests for Leukostasis

About this section
Sources

Anatomical Context for Leukostasis

About this section

MalaCards organs/tissues related to Leukostasis:

40
Myeloid, Lung, Endothelial, Retina, Neutrophil, Liver, Bone
Sources

Publications for Leukostasis

About this section

Articles related to Leukostasis:

(show top 50) (show all 568)
# Title Authors PMID Year
1
Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy. 54 61
17653050 2007
2
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. 61 54
17251488 2007
3
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. 54 61
18274606 2007
4
VEGF increases retinal vascular ICAM-1 expression in vivo. 54 61
10393052 1999
5
Hypoxic induction of interleukin-8 gene expression in human endothelial cells. 54 61
8163658 1994
6
Endotoxin-induced pulmonary leukostasis in the rat: role of platelet-activating factor and tumor necrosis factor. 54 61
8288963 1994
7
Endothelial activation antigens in pulmonary leukostasis in leukemia. 61 54
8237271 1993
8
Human recombinant interleukin-2 provokes acute pulmonary vascular endothelial injury in rabbits. 54 61
2160520 1990
9
[Changes in plasma granulocyte elastase, myeloperoxidase and fibronectin during and after open heart surgery]. 61 54
2157904 1990
10
Deletion of Thioredoxin-Interacting Protein (TXNIP) Abrogates High Fat Diet-induced Retinal Leukostasis, Barrier Dysfunction and Microvascular Degeneration in a Mouse Obesity Model. 61
32492941 2020
11
Leukostasis retinopathy treated with Anti-VEGF therapy. 61
32322747 2020
12
Inhibition of acetylcholinesterase attenuated retinal inflammation via suppressing NF-κB activation. 61
32184102 2020
13
One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. 61
31749052 2020
14
Treatment Outcome in Pediatric Acute Lymphoblastic Leukemia With Hyperleukocytosis in the Yeungnam Region of Korea: A Multicenter Retrospective Study. 61
32134842 2020
15
Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. 61
32248712 2020
16
Leukostasis retinopathy with leukemic infiltrates as onset manifestation of chronic myeloid leukemia: a case report. 61
32476461 2020
17
Swim bladder mycosis in farmed rainbow trout Oncorhynchus mykiss caused by Phoma herbarum and experimental verification of pathogenicity. 61
32270764 2020
18
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. 61
32132655 2020
19
Role of Endothelial ADAM17 in Early Vascular Changes Associated with Diabetic Retinopathy. 61
32024241 2020
20
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. 61
32019921 2020
21
Implementation of a Multidisciplinary Care Pathway via an Emergency Department-ICU to Improve Care of Emergency Department Patients Presenting With Leukostasis. 61
32211616 2020
22
Prolonged Pediatric Extracorporeal Membrane Oxygenation Support with Cardiopulmonary Failure in Juvenile Myelomonocytic Leukemia. 61
32509361 2020
23
The effect of Shengpuhuang-tang on retinal inflammation in streptozotocin-induced diabetic rats by NF-κB pathway. 61
31589966 2020
24
Rare Presentation of Bilateral Central Retinal Vein Occlusion and Leukemic Retinopathy in a Young Adult Diagnosed with T-cell Acute Lymphoblastic Leukemia. 61
32089973 2020
25
The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis. 61
31758977 2020
26
Leukostasis as a result of rapidly progressive granulocytosis in a patient diagnosed with MDS/MPN-U. 61
31805197 2019
27
Sepsis-induced Hyperleukocytosis in a Preterm. 61
31700707 2019
28
Elastic modulus and migration capability of drug treated leukemia cells K562. 61
31204049 2019
29
Acute Myeloid and Lymphoblastic Leukemia Cell Interactions with Endothelial Selectins: Critical Role of PSGL-1, CD44 and CD43. 61
31461905 2019
30
Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage. 61
31434194 2019
31
STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes. 61
31286987 2019
32
Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. 61
29475404 2019
33
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. 61
30912953 2019
34
Monosodium Urate Contributes to Retinal Inflammation and Progression of Diabetic Retinopathy. 61
30728185 2019
35
USING HISTOLOGICAL METHODS IN FORENSIC MEDICAL PRACTICE FOR DETERMINATION OF THE AGE OF INJURY TO THE PANCREAS. 61
31101788 2019
36
Longitudinal In Vivo Characterization of the Streptozotocin-Induced Diabetic Mouse Model: Focus on Early Inner Retinal Responses. 61
30811545 2019
37
Insights into the pathogenesis of cystoid macular edema: leukostasis and related cytokines. 61
31341814 2019
38
Fatal right-sided heart failure due to leukostasis in a patient with leukemic transformation of myelodysplastic syndrome. 61
30656022 2019
39
Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 × 109/L. 61
31807075 2019
40
Dexamethasone implant in the management of diabetic macular edema from clinician's perspective. 61
31190726 2019
41
Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against Pseudomonas aeruginosa lung infection. 61
30429216 2019
42
Progranulin protects the mouse retina under hypoxic conditions via inhibition of the Toll‑like receptor‑4‑NADPH oxidase 4 signaling pathway. 61
30431085 2019
43
A Contrast in Pathogenic Responses between C57BL/6J and BALB/cJ Mice Using a Model of Retinal Injury. 61
30236476 2018
44
Leukostasis retinopathy: An uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis - A case report and review of the literature. 61
30451209 2018
45
Mechanistic targeting of advanced glycation end-products in age-related diseases. 61
30279139 2018
46
Fenofibrate for Diabetic Retinopathy. 61
30058790 2018
47
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. 61
29550834 2018
48
Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. 61
29264825 2018
49
Rapid Fire: Acute Blast Crisis/Hyperviscosity Syndrome. 61
30037446 2018
50
Dexamethasone in hyperleukocytic acute myeloid leukemia. 61
29519869 2018
Sources

Variations for Leukostasis

About this section
Sources

Expression for Leukostasis

About this section
Search GEO for disease gene expression data for Leukostasis.
Sources

Pathways for Leukostasis

About this section

Pathways related to Leukostasis according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.08 VEGFA VCAM1 TNF SELL NFATC3 NFATC2
2
PEDF Induced Signaling 63
Show member pathways
 13.72 TNF SERPINF1 NFATC4 NFATC3 NFATC2 NFATC1
3
TGF-Beta Pathway 63
Show member pathways
 13.6 VEGFA TNF NFATC3 NFATC2 KDR IL6
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.4 VEGFA VCAM1 TNF IL6 IL1B ICAM1
5
TNFR1 Pathway 63
Show member pathways
 13.13 VEGFA TNF SELE NFATC2 KDR IL6
6
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.13 TNF OCLN NFATC4 NFATC3 NFATC2 NFATC1
7
Phospholipase-C Pathway 63
Show member pathways
 13.11 NFATC4 NFATC3 NFATC2 NFATC1 KDR IL6
8
fMLP Pathway 63
Show member pathways
 13.05 VEGFA NFATC4 NFATC3 NFATC2 NFATC1 KDR
9
Human cytomegalovirus infection 36
Show member pathways
 12.99 VEGFA TNF NFATC4 NFATC3 NFATC2 NFATC1
10
Allograft rejection 1 36
Show member pathways
 12.89 VEGFA TNF IL6 IL1B ICAM1
11
Measles 36
Show member pathways
 12.85 TNF IL6 IL1B ICAM1 CCL2
12
MAPK signaling pathway 36 1
12.82 VEGFA TNF NFATC3 NFATC1 KDR IL1B
13
Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling 64
Show member pathways
 12.72 VEGFA VCAM1 OCLN KDR ICAM1 CCL2
14
Immune response NFAT in immune response 22
Show member pathways
 12.69 TNF NFATC4 NFATC3 NFATC2 NFATC1
15
T cell receptor signaling pathway 36
Show member pathways
 12.67 TNF NFATC3 NFATC2 NFATC1 IL6 IL1B
16
Th17 cell differentiation 36
Show member pathways
 12.66 TNF NFATC3 NFATC2 NFATC1 IL6 IL1B
17
Immune response IL-23 signaling pathway 22
Show member pathways
 12.65 TNF MPO IL6 IL1B CCL2
18
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.65 VEGFA TNF NFATC4 NFATC2 KDR
19
Wnt signaling pathway 36
Show member pathways
 12.53 SERPINF1 NFATC4 NFATC3 NFATC2 NFATC1
20
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.52 VEGFA VCAM1 SELE NFATC1 KDR ICAM1
21
RANK Signaling in Osteoclasts 63
Show member pathways
 12.49 VCAM1 NFATC4 NFATC3 NFATC2 NFATC1 ICAM1
22
NF-kappaB Signaling 4
12.47 VCAM1 TNF NFATC4 NFATC3 NFATC2 NFATC1
23
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.43 NFATC4 NFATC3 NFATC2 NFATC1
24
Human T-cell leukemia virus 1 infection 36
12.43 TNF NFATC4 NFATC3 NFATC2 NFATC1 IL6
25
Folate Metabolism 1
Show member pathways
 12.41 TNF MPO IL6 IL1B ICAM1 CCL2
26
IL-17 Family Signaling Pathways 64
Show member pathways
 12.38 TNF IL6 IL1B CCL2
27
Pathogenic Escherichia coli infection 36
12.32 TNF OCLN IL6 IL1B
28
NOD-like receptor signaling pathway 36
12.29 TNF IL6 IL1B CCL2
29
C-type lectin receptor signaling pathway 36
Show member pathways
 12.29 TNF NFATC4 NFATC3 NFATC2 NFATC1 IL6
30
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.24 VEGFA TNF IL6 IL1B
31
Cellular senescence (KEGG) 36
12.22 NFATC4 NFATC3 NFATC2 NFATC1 IL6
32
Cell adhesion molecules (CAMs) 36
12.2 VCAM1 SELL SELE OCLN ICAM1
33
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
12.14 VEGFA VCAM1 KDR IL6
34
Osteoclast differentiation 36
12.11 TNF NFATC2 NFATC1 IL1B
35
Fluid shear stress and atherosclerosis 36
12.11 VEGFA VCAM1 TNF SELE KDR IL1B
36
Yersinia infection 36
12.1 TNF NFATC3 NFATC2 NFATC1 IL6 IL1B
37
Spinal Cord Injury 1
12.09 TNF IL6 IL1B ICAM1 CCL2
38
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.06 TNF SELL MPO IL6
39
Interleukin-4 and 13 signaling 65
12.06 VEGFA VCAM1 TNF IL6 IL1B ICAM1
40
TNF signaling pathway 36
12.03 VCAM1 TNF SELE IL6 IL1B ICAM1
41
NF-kappa B signaling pathway 36
12 VCAM1 TNF IL1B ICAM1
42
Rheumatoid arthritis 36
11.98 VEGFA TNF IL6 IL1B ICAM1 CCL2
43
Glucocorticoid receptor regulatory network 1
11.88 SELE NFATC1 IL6 ICAM1
44
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.84 TNF NFATC3 NFATC2 NFATC1
45
Dendritic Cells Developmental Lineage Pathway 64
11.82 TNF SELL IL6 IL1B
46
Pertussis 36
11.8 TNF IL6 IL1B
47
Lung fibrosis 1
11.74 TNF IL6 IL1B CCL2
48
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.72 TNF NFATC3 NFATC2 NFATC1
49
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.69 NFATC4 NFATC3 NFATC2 NFATC1
50
Legionellosis 36
11.67 TNF IL6 IL1B
Sources

GO Terms for Leukostasis

About this section

Cellular components related to Leukostasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 VEGFA TNF SERPINF1 MPO KDR IL6
2 cell surface GO:0009986 9.73 VEGFA VCAM1 TNF SELL ICAM1 AGER
3 membrane raft GO:0045121 9.67 TNF SELE KDR ICAM1
4 extracellular space GO:0005615 9.65 VEGFA VCAM1 TNF SERPINF1 SELE MPO
5 transcription factor complex GO:0005667 9.62 NFATC4 NFATC3 NFATC2 NFATC1
6 nuclear transcription factor complex GO:0044798 8.92 NFATC4 NFATC3 NFATC2 NFATC1

Biological processes related to Leukostasis according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 VEGFA TNF NFATC4 NFATC3 NFATC2 NFATC1
2 positive regulation of transcription, DNA-templated GO:0045893 10.13 TNF NFATC3 NFATC2 NFATC1 IL6 IL1B
3 positive regulation of gene expression GO:0010628 10.08 VEGFA TNF OCLN NFATC2 IL6 IL1B
4 negative regulation of gene expression GO:0010629 10.04 VEGFA TNF SERPINF1 OCLN KDR
5 response to lipopolysaccharide GO:0032496 9.98 SELE MPO IL1B ICAM1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 TNF KDR ICAM1 CCL2 AGER
7 leukocyte migration GO:0050900 9.97 TNF SELL SELE IL1B ICAM1
8 regulation of cell shape GO:0008360 9.95 VEGFA KDR ICAM1 CCL2
9 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TNF KDR IL1B AGER
10 cellular response to lipopolysaccharide GO:0071222 9.91 TNF IL6 IL1B ICAM1 CCL2
11 positive regulation of JNK cascade GO:0046330 9.88 TNF IL1B AGER
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 VEGFA TNF IL6
13 cellular response to organic cyclic compound GO:0071407 9.87 TNF IL1B CCL2
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF IL1B AGER
15 positive regulation of T cell proliferation GO:0042102 9.86 VCAM1 IL6 IL1B
16 humoral immune response GO:0006959 9.86 TNF IL6 CCL2
17 positive regulation of interleukin-6 production GO:0032755 9.86 TNF IL6 IL1B
18 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.85 VCAM1 SELE ICAM1
19 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF IL6 IL1B ICAM1 AGER
20 cellular response to amyloid-beta GO:1904646 9.83 VCAM1 ICAM1 AGER
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 TNF IL1B ICAM1
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TNF IL1B CCL2
23 positive regulation of p38MAPK cascade GO:1900745 9.8 VEGFA IL1B AGER
24 cytokine-mediated signaling pathway GO:0019221 9.8 VEGFA VCAM1 TNF IL6 IL1B ICAM1
25 branching involved in blood vessel morphogenesis GO:0001569 9.79 VEGFA NFATC4 KDR
26 leukocyte cell-cell adhesion GO:0007159 9.79 VCAM1 SELE ICAM1
27 negative regulation of neurogenesis GO:0050768 9.77 TNF IL6 IL1B
28 positive regulation of glial cell proliferation GO:0060252 9.75 TNF IL6 IL1B
29 astrocyte activation GO:0048143 9.73 TNF IL1B AGER
30 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
31 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.71 TNF IL1B AGER
32 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.7 TNF AGER
33 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 TNF IL1B AGER
35 vascular wound healing GO:0061042 9.69 VEGFA KDR
36 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.67 VEGFA KDR
37 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.67 VEGFA KDR
38 positive regulation of fever generation GO:0031622 9.67 TNF IL1B
39 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.67 TNF IL6 ICAM1
40 protein kinase B signaling GO:0043491 9.67 TNF KDR IL1B CCL2
41 membrane to membrane docking GO:0022614 9.66 VCAM1 ICAM1
42 positive regulation of chemokine biosynthetic process GO:0045080 9.65 TNF IL1B AGER
43 sequestering of triglyceride GO:0030730 9.64 TNF IL1B
44 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 TNF IL1B
45 cytokine production GO:0001816 9.62 NFATC4 NFATC3 NFATC2 NFATC1
46 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6 IL1B
47 negative regulation of vascular smooth muscle cell differentiation GO:1905064 9.58 NFATC3 NFATC2 NFATC1
48 inflammatory response GO:0006954 9.56 TNF SELE NFATC4 NFATC3 IL6 IL1B
49 leukocyte tethering or rolling GO:0050901 9.46 VCAM1 TNF SELL SELE
50 calcineurin-NFAT signaling cascade GO:0033173 8.92 NFATC4 NFATC3 NFATC2 NFATC1

Molecular functions related to Leukostasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 VEGFA TNF SERPINF1 SELL SELE RMC1
2 chromatin binding GO:0003682 9.65 NFATC4 NFATC3 NFATC2 NFATC1 MPO
3 integrin binding GO:0005178 9.46 VCAM1 KDR IL1B ICAM1
4 oligosaccharide binding GO:0070492 9.32 SELL SELE
5 cytokine activity GO:0005125 9.02 VEGFA TNF IL6 IL1B CCL2
Sources

Sources for Leukostasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....